The report provides a detailed analysis essential for establishing an Adalimumab production plant. It encompasses all critical aspects necessary for Adalimumab production, including the cost of Adalimumab production, Adalimumab plant cost, Adalimumab production costs, and the overall Adalimumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Adalimumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Adalimumab is a human monoclonal antibody that attaches to tumor necrosis factor alpha (TNF-α) and neutralizes its inflammatory effects. Adalimumab reduces inflammation and symptoms of certain autoimmune and inflammatory disorders by blocking TNF-α, making it a useful drug to treat various conditions. It is used in the treatment of psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis, as it reduces pain and swelling by blocking TNF.
Adalimumab is used for treating hidradenitis suppurativa, treat plaque-type psoriasis, and other skin conditions. Its anti-inflammatory property is further utilized in treating several bowel conditions like ulcerative colitis and Crohn's disease. Adalimumab is also used for treating eye diseases like uveitis reducing inflammation and pain.
The procurement of Adalimumab is driven by its diverse therapeutic applications, including the treatment of several autoimmune and inflammatory conditions. It treats conditions like arthritis, skin disorders, bowel diseases, and eye diseases, increasing its demand significantly.
Its property in successfully blocking TNF-α and reducing inflammation and tissue damage further enhances its value in the market. Collectively, the combination of Adalimumab's therapeutic efficacy, expanding patient population, and the competitive biosimilar landscape, along with its production prices, market prices, and logistics, directly influence industrial Adalimumab procurement in the market across the globe.
Raw Material for Adalimumab Production
According to the Adalimumab production plant project report, the key raw materials used in the production of Adalimumab include Chinese Hamster Ovary (CHO) cell lines, hydrolysates (like Primatone and yeastolate)-excipients.
Production Process of Adalimumab
The extensive Adalimumab production cost report consists of the following major industrial production process:
- From Chinese Hamster Ovary (CHO) cell lines, hydrolysates and excipients: The production of Adalimumab is done using a thorough process. First, a stable CHO cell line capable of high yields is selected. The culturing of these CHO cells is done in a perfusion bioreactor system, and the culture media is optimized using hydrolysates like (Primatone and Yeastolate) that support high cell densities and productivity. After that, it goes through multiple purification steps, such as filtration, chromatography, and viral clearance. The overall yielding of the final drug is 79%, which is further formulated with additional excipients and filled into vials for commercial distribution.
Adalimumab is a clear, colorless solution with a pH of about 5.2. Its molecular weight is around 148 kDa, consisting of 1,330 amino acids. Adalimumab works by binding to and blocking the pro-inflammatory TNF. By modulating the biological responses regulated by TNF-α, Adalimumab can influence factors like adhesion molecule levels, which are responsible for the migration of leukocytes (white blood cells). The isoelectric point of Adalimumab is reported to be 8.25. Adalimumab's unique physicochemical properties make it useful in treating a range of autoimmune and inflammatory conditions.